SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

19 May 2022 Evaluate
The company witnessed a 24.25% growth in the revenue at Rs. 11030.14 millions for the quarter ended March 2022 as compared to Rs. 8877.48 millions during the year-ago period.A slim rise of 9.80% was recorded in the Net profit for the quarter ended March 2022 to Rs. 2859.76  millions  From Rs. 2604.51 millions.Operating profit for the quarter ended March 2022 rose to 4136.65 millions as compared to 3749.28 millions of corresponding quarter ended March 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 11030.14 8877.48 24.25 44007.08 34628.76 27.08 44007.08 34628.76 27.08
Other Income 652.34 472.14 38.17 2239.40 1347.76 66.16 2239.40 1347.76 66.16
PBIDT 4136.65 3749.28 10.33 17345.79 14370.43 20.70 17345.79 14370.43 20.70
Interest 20.32 10.21 99.02 52.40 34.11 53.62 52.40 34.11 53.62
PBDT 4116.33 3739.07 10.09 17293.39 14336.32 20.63 17293.39 14336.32 20.63
Depreciation 310.75 249.22 24.69 1102.96 987.80 11.66 1102.96 987.80 11.66
PBT 3805.58 3489.85 9.05 16190.43 13348.52 21.29 16190.43 13348.52 21.29
TAX 945.82 885.34 6.83 4068.88 3378.47 20.44 4068.88 3378.47 20.44
Deferred Tax 93.23 13.13 610.05 140.08 1.20 11573.33 140.08 1.20 11573.33
PAT 2859.76 2604.51 9.80 12121.55 9970.05 21.58 12121.55 9970.05 21.58
Equity 164.30 163.59 0.43 164.30 163.59 0.43 164.30 163.59 0.43
PBIDTM(%) 37.50 42.23 -11.20 39.42 41.50 -5.02 39.42 41.50 -5.02

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×